drugset / Trial / NCT07040839

Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection

NCT07040839

Phase 4 Not yet recruiting 128 enrolled Rehman Medical Institute - RMI
RandomizedParallel-groupOpen-labelTreatment

Summary

Current studies have primarily focused on comparing the advantages and disadvantages of P-CAB and PPI drugs, with little comparison between different P-CAB drugs or between regimens with varying drug combinations and treatment durations. This study aims to evaluate the clinical effectiveness of vonoprazan-based H. pylori eradication therapy and compare it to that of conventional PPI based therapy in clinical practice.

Timeline

Start
2025-07
Primary completion
2026-02
Completion
2026-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g Oral
Subject Clarithromycin Small molecule 500 mg Oral
Subject Levofloxacin Small molecule 500 mg Oral
Subject Omeprazole Other / unclassified 40 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral